Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1

Conditions

Neoplasms 7Multiple Myeloma 4Sarcoma 3Leukemia 3Kidney Neoplasms 3Glioma 3Brain Neoplasms 3Waldenstrom Macroglobulinemia 2Sarcoma, Alveolar Soft Part 2Recurrence 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Oligodendroglioma 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Glioblastoma 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Astrocytoma 2Unspecified Adult Solid Tumor, Protocol Specific 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Sarcoma, Synovial 1Sarcoma, Endometrial Stromal 1Salivary Gland Neoplasms 1Rhabdomyosarcoma 1Ovarian Neoplasms 1

Interventions

Cyclophosphamide 153Dexamethasone 141Rituximab 85fludarabine 79Lenalidomide 72Cytarabine 70Bortezomib 64fludarabine phosphate 63Gemcitabine 62venetoclax 54Etoposide 53pomalidomide 52pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × perifosine × Clear all
NCT00401011 2018-02-23

Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients

AEterna Zentaris

Phase 1/2 Completed
84 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT01049841 2017-03-10

Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
23 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡